These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30844538)

  • 1. Structural perspectives of antibody-dependent enhancement of infection of dengue virus.
    Morrone SR; Lok SM
    Curr Opin Virol; 2019 Jun; 36():1-8. PubMed ID: 30844538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
    Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
    Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection.
    Wang Y; Si LL; Guo XL; Cui GH; Fang DY; Zhou JM; Yan HJ; Jiang LF
    Virus Res; 2017 Feb; 229():57-64. PubMed ID: 27939945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
    Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.
    da Silva Voorham JM; Rodenhuis-Zybert IA; Ayala Nuñez NV; Colpitts TM; van der Ende-Metselaar H; Fikrig E; Diamond MS; Wilschut J; Smit JM
    PLoS One; 2012; 7(3):e29957. PubMed ID: 22431958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.
    Shi X; Deng Y; Wang H; Ji G; Tan W; Jiang T; Li X; Zhao H; Xia T; Meng Y; Wang C; Yu X; Yang Y; Li B; Qin ED; Dai J; Qin CF; Guo Y
    MAbs; 2016; 8(3):574-84. PubMed ID: 26905804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus.
    Ripoll DR; Wallqvist A; Chaudhury S
    Front Cell Infect Microbiol; 2019; 9():200. PubMed ID: 31275864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity.
    Moi ML; Lim CK; Tajima S; Kotaki A; Saijo M; Takasaki T; Kurane I
    J Clin Virol; 2011 Nov; 52(3):225-30. PubMed ID: 21824813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
    Gelanew T; Hunsperger E
    Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity.
    Dent M; Hurtado J; Paul AM; Sun H; Lai H; Yang M; Esqueda A; Bai F; Steinkellner H; Chen Q
    J Gen Virol; 2016 Dec; 97(12):3280-3290. PubMed ID: 27902333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM.
    Luo Y; Guo X; Yan H; Fang D; Zeng G; Zhou J; Jiang L
    Appl Microbiol Biotechnol; 2015 Jul; 99(14):5917-27. PubMed ID: 25822571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
    Ayala-Nuñez NV; Jarupathirun P; Kaptein SJ; Neyts J; Smit JM
    Antiviral Res; 2013 Oct; 100(1):238-45. PubMed ID: 23994499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.